Cytori Therapeutics, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cytori Therapeutics, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: SnowShredder	3/16/2012 9:39:44 AM
	of 251

FDA Grants Cytori 510(k) Clearance for Puregraft(R) 850 SAN DIEGO, CA--(Marketwire -03/16/12)- Cytori (NASDAQ: CYTX - News) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Puregraft® 850 System for body contouring using a patient's own fat. The Puregraft® 850 product line extension provides optimized and sterile processing of up to 850 mL of tissue, a significantly larger volume than the Puregraft® 250, which received a 510(k) in January 2010. Larger tissue volumes expand the range of soft tissue procedures for which the product line may be used. The Puregraft® products are best-in-class innovative products which standardize the preparation of fat grafts. Puregraft® technology has been rapidly adopted since the original launch in 2010. Fat grafting is an important trend in reconstructive and aesthetic surgery, with broad applications in soft tissue procedures. The Puregraft® 850 System has also received European approval and will soon be launched in both the EU and US. According to the American Society of Plastic Surgeons' most recent report, more than 57,000 fat grafting procedures were performed in the United States in 2010, a 14% increase over the previous year. <snip> finance.yahoo.com Best of Luck, SS

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next